Dergiler / Turkish Journal of Endocrinology and Metabolism / 2019 / Cilt: 23 - Sayı: 1

Transient Elevation of CA 19-9 Due to Cessation of Levothyroxine in a Patient with Hashimoto’s Thyroiditis

Hashimoto Tiroiditi Olan Bir Hastada Levotiroksinin Kesilmesi Nedeni ile Geçici CA 19-9 Yükselmesi

Sayfa
68–71
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

On the basis of the present case study, we propose that hypothyroidism should be considered while making a differential diagnosis for patients with elevated levels of CA 19-9.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Serum CA 19-9 (carbohydrate antigen 19-9) is a tumor marker with monosialoganglioside structure.
📊
Temel Bulgular & Veri:Although significant elevation in the levels of CA 19-9 indicates malignancy, an underlying malignant disease may not always be determined, and benign pathologies may also be observed.
💡
Sonuç & Katkı:On the basis of the present case study, we propose that hypothyroidism should be considered while making a differential diagnosis for patients with elevated levels of CA 19-9.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Serum CA 19-9 (carbohydrate antigen 19-9) is a tumor marker with monosialoganglioside structure. Its levels are measured frequently for screening purposes in daily practice by physicians, while its main application is in the study of tumor recurrence and the follow-up of the recurrences. Although significant elevation in the levels of CA 19-9 indicates malignancy, an underlying malignant disease may not always be determined, and benign pathologies may also be observed. A 45-year-old female patient who was undergoing a follow-up for Hashimoto’s thyroiditis applied to our clinic with complaints of fatigue, tiredness, and hair loss. Elevations in the levels of both thyroid-stimulating hormone (TSH) and CA 19-9 were observed. The levels of TSH and CA 19-9 were observed to be normal after the patient was treated for hypothyroidism, and the results of the analysis conducted for malignancy were also determined to be normal. On the basis of the present case study, we propose that hypothyroidism should be considered while making a differential diagnosis for patients with elevated levels of CA 19-9.

Abstract

Serum CA 19-9 (karbonhidrat antijeni 19-9); monosialogangliosid yapıda bir tümör belirtecidir. Günümüzde asıl kullanım amacı olan tümörün rekürrens ve nüks takibi dışında günlük pratikte hekimler tarafından sıklıkla tarama amaçlı olarak da düzeyine bakılmaktadır. Her ne kadar CA 19-9 düzeyindeki belirgin yükseklikler maligniteye yönlendirme açısından şüphe uyandırsa da her zaman altta yatan malign hastalık saptanmayıp, benign patolojiler de görülebilmektedir. Hashimoto tiroiditi ile takipli 45 yaşındaki kadın hasta; hâlsizlik, yorgunluk ve saç dökülmesi şikâyetleri ile kliniğimize başvurdu. Yapılan incelemelerde, TSH ve CA 19-9 yüksekliği olduğu görüldü. Malignite taramaya yönelik yapılan tetkik sonuçları normal saptanan hastada, hipotiroidi tedavisi sonrası normal TSH ve CA 19-9 düzeyi olduğu bulundu. Hastamızda da olduğu gibi, CA 19-9 yüksekliği saptanan bir bireyde ayırıcı tanı yapılır iken hipotiroidinin de akılda bulundurulması gerektiği düşünülmektedir.

🔖

Bu Makaleye Atıf Yap

KOCA, A. O., ALTAY, M. (2019). Transient Elevation of CA 19-9 Due to Cessation of Levothyroxine in a Patient with Hashimoto’s Thyroiditis. Turkish Journal of Endocrinology and Metabolism, Cilt: 23 - Sayı: 1, 68–71. https://ajindex.com/articles/370742

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Ventrucci M, Pozzato P, Cipolla A, Uomo G. Persistent elevation of serum CA 19-9 with no evidence of malignant disease. Dig Liver Dis. 2009
  2. [Crossref] [PubMed] 2. Kim MS, Jeon TJ, Park JY, Choi J, Shin WC, Park SE, Seo JY, Kim YM. Clinical interpretation of elevated CA 19-9 levels in obstructive jaundice following benign and malignant pancreatobiliary disease. Korean J Gastroenterol. 2017
  3. [Crossref] [PubMed] 3. Bertino G, Ardiri AM, Calvagno GS, Malaguarnera G, Interlandi D, Vacante M, Bertino N, Lucca F, Madeddu R, Motta M. Carbohydrate 19.9 antigen serum levels in liver disease. Biomed Res Int. 2013
  4. 531640. [Crossref] [PubMed] [PMC] 4. Fania C, Pezzilli R, Melzi d’Eril G, Gelfi C, Barassi A. Identification of small proteins and peptides in the differentiation of patients with intraductal mucinous neoplasms of the pancreas, chronic pancreatitis and pancreatic adenocarcinoma. Dig Dis Sci. 2018
  5. [Crossref] [PubMed] 5. Romero Estarlich V, González-Senac NM, Yulissa Peña Lora D, Vidán Astiz MT, Serra Rexach JA. [Progressive elevation of CA 19-9 tumour marker in a nonagenarian with advanced idiopathic pulmonary fibrosis]. Rev Esp Geriatr Gerontol. 2018
  6. [Crossref] [PubMed] 6. Kim HJ, Kim MH, Myung SJ, Lim BC, Park ET, Yoo KS, Seo SK, Min YI. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve. Am J Gastroenterol. 1999
  7. [Crossref] [PubMed] 7. Morris-Stiff G, Teli M, Jardine N, Puntis MC. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease. Hepatobiliary Pancreat Dis Int. 2009
  8. [PubMed] 8. Parra JL, Kaplan S, Barkin JS. Elevated CA 19-9 caused by Hashimoto’s thyroiditis: review of the benign causes of increased CA 19-9 level. Dig Dis Sci. 2005
  9. [Crossref] [PubMed] 9. Jamaludin AZ, Metassan MM, Zainal-Abidin Z, Chong VH. Elevated serum CA 19-9 in association with Hashimoto’s thyroiditis. Singapore Med J. 2010
  10. e143-145. [PubMed] 10.Takahashi N, Shimada T, Ishibashi Y, Oyake N, Murakami Y. Transient elevation of serum tumor markers in a patient with hypothyroidism. Am J Med Sci. 2007
  11. [Crossref] [PubMed] 11.Tekin O. Hypothyroidism-related CA 19-9 elevation. Mayo Clin Proc. 2002
  12. [Crossref] [PubMed] 12.Hashimoto T, Matsubara F. Changes in the tumor marker concentration in female patients with hyper-, eu-, and hypoth